Verdiva Bio

Clinical-stage biotech developing once-weekly oral and injectable GLP-1 and amylin drugs for obesity and cardiometabolic disease, licensed from China's Sciwind.

View on the globe

$411MEquity raised in 2025–20262025 $411M · 2026 — · 1 equity round
$411MEquity raised, all time1 equity round on record
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 1 round from 9 Jan 2025 to 9 Jan 2025, $411M equity disclosed.9 Jan 2025: Series A, $411M$10M$30M$100M$300M$1BQ3Q42025Q2Q3Q4Equity round9 Jan 2025 · Series A · $411M · led by Forbion, General AtlanticSeries A · $411M
Funding history: 1 round from 9 Jan 2025 to 9 Jan 2025, $411M equity disclosed.9 Jan 2025: Series A, $411M$10M$30M$100M$300M$1BQ3Q42025Q2Q3Q4Equity round9 Jan 2025 · Series A · $411M · led by Forbion, General Atlantic$411M

Funding history 1 round · 3 sources

  1. Series A
    Amount$411M
    Post-money—
    ✓ Confirmed
    Lead
    Forbion, General Atlantic
    Also
    RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, LYFE Capital
    Note
    Launch round and first financing, co-led by Forbion and General Atlantic; Tech.eu and BioPharma Dive both report $411M. Valuation undisclosed.
    Sources

Investors 7

  • Forbion1
  • General Atlantic1
  • Lilly Asia Ventures
  • Logos Capital
  • LYFE Capital
  • OrbiMed
  • RA Capital Management

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the London hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Verdiva Bio and its logo are trademarks of their owners, used here for identification only.